Albiruni Abdul Razak, MB BCh, BAO, LRCP & SI

Toronto Sarcoma Program, Princess Margaret Cancer Center
Toronto, Ontario, Canada

Disclosure information not submitted.

Presentation(s):

• Paper 43 - BRIGIMADLIN VERSUS STANDARD-OF-CARE DOXORUBICIN AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED DEDIFFERENTIATED LIPOSARCOMA (DDLPS): BRIGHTLINE-1

  Friday, November 15, 2024
  9:00 AM – 10:00 AM PST

• Paper 78 - A MULTICENTER, RANDOMIZED, PHASE 3 STUDY OF INTRATUMORAL INT230-6 (SHAO, VINBLASTINE, CISPLATIN) COMPARED TO STANDARD OF CARE THERAPY IN SELECTED METASTATIC SOFT TISSUE SARCOMAS: INVINCIBLE-3 TRIAL.

  Saturday, November 16, 2024
  9:00 AM – 10:00 AM PST

• Paper 84 - PLANNED ANALYSIS OF THE PIVOTAL IGNYTE-ESO TRIAL OF LETE-CEL IN PATIENTS WITH SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA.

  Saturday, November 16, 2024
  10:30 AM – 12:00 PM PST

• Paper 105 - EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES OF VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR: RESULTS FROM THE MOTION PHASE 3 TRIAL

  Saturday, November 16, 2024
  3:30 PM – 4:30 PM PST